Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer (FRA:BAYN) in a research report released on Monday, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other research firms have also issued reports on BAYN. Barclays set a €85.00 ($98.84) price target on Bayer and gave the stock a buy rating in a research report on Friday, October 25th. HSBC set a €63.00 ($73.26) price target on Bayer and gave the stock a neutral rating in a research report on Wednesday, August 7th. Nord/LB set a €64.00 ($74.42) price target on Bayer and gave the stock a neutral rating in a research report on Wednesday, October 30th. Deutsche Bank set a €70.00 ($81.40) price target on Bayer and gave the stock a neutral rating in a research report on Thursday, October 31st. Finally, Sanford C. Bernstein set a €90.00 ($104.65) price target on Bayer and gave the stock a buy rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company. Bayer currently has a consensus rating of Hold and an average price target of €80.47 ($93.57).
BAYN traded down €0.06 ($0.07) during trading on Monday, reaching €70.19 ($81.62). 2,337,006 shares of the company were exchanged. The company’s 50-day moving average is €66.89 and its two-hundred day moving average is €61.74. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: Why is total return important?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.